Rhythm Biosciences (ASX:RHY) said that it has retained its ISO 13485:2016 certification for the seventh year from the UK's British Standards Institution (BSI), according to a Monday filing with the Australian bourse.
This year's certification also includes an expanded scope, now covering the design, manufacturing, distribution, installation, and servicing of in-vitro medical devices, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.